Purple Biotech vs Tharimmune

Purple Biotech vs Tharimmune, compared side by side on 14 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Purple Biotech is on 20/100 and Tharimmune on 53/100.

Purple Biotech logo
Purple BiotechClinical-stage company developing novel oncology therapies to overcome tumor immune evasion and drug resistance.
Try Purple Biotech
Tharimmune logo
TharimmuneBiotechnology company developing novel immunotherapies for cancer.
Try Tharimmune

Where each one leads

Purple Biotech

  • agent readiness: 50/100 against 31/100
  • headcount: 19 against 13

Tharimmune

  • our overall score: 53/100 against 20/100

At a glance

MeasurePurple BiotechTharimmune
What it isClinical-stage company developing novel oncology therapies to overcome tumor immune evasion and drug resistance.Biotechnology company developing novel immunotherapies for cancer.
CategoryBiotech, Life Sciences, Drug Discovery, Clinical TrialsBiotech, MedTech, HealthTech, Drug Discovery
Sells toBusiness modelB2BB2B
OfferingServicesServices
Founded20132017
HeadquartersTel Aviv, IsraelCambridge, United States
StatusActiveActive

Size, funding and growth

MeasurePurple BiotechTharimmune
Employees1913
Total fundingNot published$540M
Latest roundBootstrappedNot published
LinkedIn followers1,4301,718

StartupHub scores

Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.

MeasurePurple BiotechTharimmune
StartupHub scoreOur 0-100 rating20/10053/100
Traction13/10051/100
TeamNot published70/100
CommunityNot published15/100
Search visibility25/10022/100
QualityNot published58/100
Agent readinessHow well an AI agent can read and act on the siteD (50/100)F (31/100)
Domain ratingLink authority, 0-10026/10026/100

Technology

Detected on each public site, so it reflects the marketing stack as well as the product.

MeasurePurple BiotechTharimmune
HostingGoogle CloudNot detected
CDNNot detectedCloudflare
CMSNot detectedWebflow

What users say

MeasurePurple BiotechTharimmune
Reddit sentimentThreads we track4 positive, 0 negative across 6 threadsNot published
Purple Biotech
Purple Biotech presenta nuevos datos preclínicos en EACR 2026 que destacan la actividad antitumoral de IM1240, su favorable perfil de seguridad y farmacocinético, y su amplio margen terapéutico.
r/biotech_stocks

Purple Biotech vs Tharimmune: common questions

Which is better, Purple Biotech or Tharimmune?

On our 0-100 score Tharimmune rates higher (53/100 against 20/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 14 data points above: read the rows that match what you are buying for.

How do Purple Biotech and Tharimmune compare on the numbers?

Purple Biotech leads on agent readiness (50/100 against 31/100), headcount (19 against 13). Tharimmune leads on our overall score (53/100 against 20/100).

What do real users say about Purple Biotech and Tharimmune?

Purple Biotech: 4 positive and 0 negative mentions across 6 Reddit threads we track, mostly in r/biotech_stocks.

Read the full Purple Biotech review and pricing or the Tharimmune review and pricing. You can also browse other Purple Biotech alternatives we track.